Shaji K Kumar

Dec 3, 2024 | onclive.com | Shaji K Kumar

“When you have a newly diagnosed patient with myeloma, doing imaging to make sure you make an accurate diagnosis of myeloma vs one of the precursive conditions [is important].”Shaji Kumar, MD, research chair, consultant, Division of Hematology, professor, medicine, Mayo Clinic, discusses notable therapy considerations for multiple myeloma following the 2024 and first quarter of 2025 National Comprehensive Cancer Network (NCCN) guidelines update.

Nov 27, 2024 | onclive.com | Shaji K Kumar

"We did a major update for the treatment of relapsed/refractory disease, wherein the major change has been the introduction of immunotherapy over the past year; even though some of the agents were already there, we restructured the approach.”Shaji Kumar, MD, research chair, Division of Hematology, consultant, Division of Hematology, professor, medicine, Mayo Clinic, discusses 2024 and first quarter of 2025 National Comprehensive Cancer Network (NCCN) updates for multiple myeloma treatment.

Apr 14, 2024 | onlinelibrary.wiley.com | Matthew Rees |Shaji K Kumar |Ashby TC

CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest. REFERENCES 1, , , et al. Real-world results of autologous stem cell transplantation in newly diagnosed patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database. Blood. 2022; 140(Suppl 1): 289-291. 2, , , et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28(5): 1122-1128.

Jan 22, 2024 | onclive.com | Jeffrey Zonder |Shaji K Kumar

Dr. Zonder and Dr. Kumar share their clinical pearls and perspectives on future directions in the treatment of AL amyloidosis.

Jan 22, 2024 | onclive.com | Jeffrey Zonder |Shaji K Kumar

ctDNA Is Predictive of DFS, Offers Prognostic Tool in CRCFrontline Nivolumab/Ipilimumab Provides Superior PFS Benefit Over Chemo in MSI-H/dMMR mCRCDr Li on the Use of ADG126 With Pembrolizumab in MSS CRCReal-World Data Identify Factors Associated With Long-Term Response to Regorafenib in mCRC